Skip to main content

SAGE

Stock
Health Care
Biotechnology

Performance overview

SAGE Price
Price Chart

Forward-looking statistics

Beta
1.95
Risk
75.52%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.

Company info

SectorHealth Care
IndustryBiotechnology
Employees633
Market cap$636.7M

Fundamentals

Enterprise value—
Revenue—
Revenue per employee—
Profit margin—
Debt to equity—

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)—
Dividend per share—
Revenue per share—
Avg trading volume (30 day)—
Avg trading volume (10 day)—
Put-call ratio—

Macro factor sensitivity

Growth+1.2
Credit+6.0
Liquidity-0.0
Inflation-1.7
Commodities-0.8
Interest Rates-1.8

Valuation

Dividend yield0.00%
PEG Ratio—
Price to sales—
P/E Ratio-1.53
Enterprise Value to Revenue—
Price to book—

Upcoming events

Next earnings dayApril 30, 2025
Next dividend day—
Ex. dividend day—

News

What Makes Sage Therapeutics (SAGE) a New Buy Stock

Sage Therapeutics (SAGE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research (July 1, 2025)
These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News

Supernus Pharmaceuticals, Inc. SUPN on Monday agreed to acquire Sage Therapeutics, Inc. SAGE for $12.00 per share in cash, or an aggregate of up to approximately $795 million.

Benzinga (June 17, 2025)
Top 3 Health Care Stocks That Are Ticking Portfolio Bombs

As of June 17, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Benzinga (June 17, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free